The mission of the OSUCCC Real Time PCR Shared Resource (RT PCR SR) is to advance the quality of cancer research while increasing productivity of OSUCCC members at reduced costs through providing high quality instrumentation and expert resources. Quantitative real time polymerase chain reaction (QRT-PCR) provides a rapid and accurate method for determination of levels of specific DNA and RNA sequences from tissue samples. It is based on detection of a fluorescent signal produced proportionately during amplification of a PCR product. However, current technology is associated with high costs for reagents, instrumentation, setup, erroneous design/data interpretation and maintenance. For this reason, QRT-PCR expertise and instrumentation are made available to OSUCCC investigators as well as to OSU researchers at large through the RT PCR. The Applied Biosystem's Prism 7700 instrument and expert personnel are located in the Tzagournis Medical Research Facility (TMRF) that is at the center of the OSU Medical Center complex. Over the past two years since this was transitioned from a developmental to a full SR, 52 members, representing 6 of the 60SUCCC Programs, have used the resource, making up >82% of the overall RT PCR usage. To meet the needs of and to ensure the RT PCR SR is accessible to all OSUCCC members, nine services in addition to instrument self-service and training have been added: consultations, primer/probe design, technicianperformed service, aid in developing grants pertaining to Real Time PCR, a website for convenient on-line scheduling and a database of optimized Real Time PCR primers, data analysis/interpretation, data archiving and an in-house store of common reagents and disposables. Based on grants funded in the last year, grants in review, and grants to be submitted in the next year, the current projection in usage of the RT PCR SR's main facility by OSUCCC members is an increase of greater than 2.5 times the current usage. To meet and exceed the RT PCR SR's main goals to increase productivity in a cost-effective manner and advance the quality of cancer research by OSUCCC members, some cost sharing for instrumentation upgrades and new services are proposed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-34
Application #
7743482
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2010-11-30
Budget Start
2008-12-01
Budget End
2010-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$72,166
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Volinia, Stefano; Bertagnolo, Valeria; Grassilli, Silvia et al. (2018) Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells. Oncotarget 9:23543-23553

Showing the most recent 10 out of 2602 publications